Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Gains from Investment Securities (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Gains from Investment Securities data on record, last reported at $611325.0 in Q3 2022.

  • For Q3 2022, Gains from Investment Securities rose 284.04% year-over-year to $611325.0; the TTM value through Sep 2022 reached $611325.0, up 284.04%, while the annual FY2025 figure was $485000.0, N/A changed from the prior year.
  • Gains from Investment Securities reached $611325.0 in Q3 2022 per AVIR's latest filing, down from $724970.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $10.5 million in Q4 2021 and bottomed at $159183.0 in Q3 2021.
  • Average Gains from Investment Securities over 3 years is $2.4 million, with a median of $1.0 million recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: crashed 95.33% in 2021, then skyrocketed 284.04% in 2022.
  • A 3-year view of Gains from Investment Securities shows it stood at $3.4 million in 2020, then surged by 208.52% to $10.5 million in 2021, then tumbled by 94.19% to $611325.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $611325.0 in Q3 2022, $724970.0 in Q2 2022, and $2.9 million in Q1 2022.